62nd ASH Annual Meeting and Exposition: 651. Myeloma: Biology and Pathophysiology, excluding Therapy II

Oral and Poster Abstracts
Oral

Adult, Biological, multiple myeloma, Diseases, biopsy, CAR-Ts, Therapies, Biological Processes, immune cells, Technology and Procedures, Cell Lineage, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, genomics, flow cytometry, immune mechanism, integrative -omics, molecular testing, NGS, microenvironment, RNA sequencing, WGS

Moderators:

Frits van Rhee, MD, University of Arkansas For Medical Sciences and Samir S. Parekh, MD, Icahn School of Medicine at Mount Sinai

Disclosures:

van Rhee: Adaptive Biotech: Consultancy; Takeda: Consultancy; EUSA: Consultancy; CDCN: Consultancy; Karyopharm: Consultancy; Sanofi: Consultancy; GlaxoSmith Kline: Consultancy; Karyopharm: Consultancy. Parekh: Foundation Medicine: Consultancy; Celgene: Research Funding; Karyopharm: Research Funding.

1:30 PM

719

Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Noemie Leblay, PhD¹^*, Ranjan Maity, PhD¹^*, Elie Barakat¹^*, Sylvia McCulloch, MD, MSc², Peter Duggan, MD, FRCPC², Victor Jimenez-Zepeda, MD², Nizar Bahlis, MD³ and Paola Neri, MD¹

¹Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
²Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, AB, Canada
³University of Calgary, Calgary, AB, Canada

1:45 PM

720

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Luca Bertamini, MD^*, Mariella Grasso^*, Mattia D'Agostino, MD^*, Anna Pascarella^*, Patrizia Tosi^*, Federico Monaco^*, Francesco Pisani^*, Paola Bertazzoni^*, Milena Gilestro^*, Andrea Capra^*, Piero Galieni^*, Ombretta Annibali^*, Vincenzo Pavone^*, Stefano Molica, MD, Sonia Ronconi^*, Paola Tacchetti^*, Pellegrino Musto, Francesca Gay, MD, Mario Boccadoro and Stefania Oliva^*

GIMEMA, European Myeloma Network, Italy

2:00 PM

721

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD^1,2, Mariateresa Fulciniti, PhD³, Anil Aktas-Samur, PhD^4,5^*, Abdul Hamid Bazarbachi, MD⁶^*, Yu-Tzu Tai, PhD⁷, Timothy B. Campbell, MD, PhD⁸^*, Fabio Petrocca, MD⁹^*, Kristen Hege, MD⁸, Shari Kaiser, PhD⁸^*, Kenneth Anderson, MD^3,10 and Nikhil C. Munshi, MD^11,12

¹Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
³The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Department of Data Science, Dana Farber Cancer Institute, Boston, MA
⁵Harvard School of Public Health, Boston, MA
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Paris, France
⁷Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Bristol Myers Squibb, Princeton, NJ
⁹bluebird bio, Cambridge, MA
¹⁰Harvard Medical School, Boston, MA
¹¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹²Boston VA Healthcare System, West Roxbury, MA

2:15 PM

722

Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Maximilian Merz, MD¹^*, Almuth Maria Anni Merz, MD²^*, Jie Wang, PhD³^*, Lei Wei, PhD²^*, Ahmed Belal, MD⁴^*, Ronald Alberico, MD⁴^*, Qiang Hu, PhD³^*, Cherie Rondeau, NP³^*, Kimberly Celotto, NP³^*, AnneMarie W. Block, PhD², Hemn Mohammadpour, PhD⁵, Megan M. Herr, PhD⁶^*, Theresa E. Hahn, PhD⁶, Paul K. Wallace, MS, PhD², Joseph Dennis Tario, PhD²^*, Jesse Luce⁴^*, Sean Glenn, PhD⁴^*, Prashant K Singh, PhD⁷^*, Kelvin P. Lee, MD², Song Liu, PhD⁸^*, Philip L. McCarthy, MD⁹ and Jens Hillengass, MD, PhD¹⁰

¹Roswell Park Comprehensive Cancer Center Institute, Buffalo, NY
²Roswell Park Comprehensive Cancer Center, Buffalo, NY
³Roswell Park Comprehensive Cancer Center, Buffalo
⁴Roswell Park Cancer Institute, Buffalo, NY
⁵Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁶Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁷Center for Personalized Medicine, Roswell Park Cancer Comprehensive Cancer Center, Buffalo, NY
⁸Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁹Department of Medicine, Blood and Marrow Transplant Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY
¹⁰Roswell Park, Buffalo, NY

2:30 PM

723

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, PhD¹^*, Shirong Li¹^*, Huihui Ma, MD, PhD²^*, Jun Yang, MS¹^*, Gabriel M. Pagnotti, Ph.D.³^*, Stephen J. Weiss, MD, PhD⁴^*, Markus Y Mapara, MD, PhD² and Suzanne Lentzsch, MD, PhD¹^*

¹Division of Hematology and Oncology, Columbia University Medical Center, New York, NY
²Columbia Center for Translational Immunology, Columbia University, New York, NY
³Indiana University School of Medicine, Indianapolis, IL
⁴Department of Internal Medicine, University of Michigan, Life Sciences Institute, Ann Arbor, MI

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651A.O1.6 651. Myeloma: Biology and Pathophysiology, excluding Therapy II